$617 MillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$6.10 - $22.74The lowest and highst price in the last 52 weeks.
0.0xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$617 Million|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||-54.1%|
|Outstanding Shares||73.7 Million|
|Avg 30 Day Volume||1.93 Million|
|Earnings per Share||$0.00|
|Price to Sales Ratio||-|
|Price to Book Ratio||-|
|Revenue to Enterprise Value||-|
|EBIT to Enterprise Value||-|
|Total Debt to Enterprise Value||-|
|Debt to Equity||-|
|Quarterly Earnings Growth (YoY)||-|
|Return on Equity||-|
|Return on Assets||-|
|Return on Invested Capital||-|
CEO: Rick Winningham
Industry: Pharmaceutical Preparation Manufacturing
Theravance Biopharma, Inc. (NASDAQ:TBPH) has earned an average rating of Hold from the nine ratings firms that are covering the company, MarketBeat reports. ...Transcript Daily, about 2 months ago
Full story available on Benzinga.comBenzinga, 2 months ago
JPMorgan Chase & Co. upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from an underweight rating to a neutral rating in a report issued on Friday, Analy...Transcript Daily, 2 months ago
Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock analysts at SVB Leerink upped their Q3 2022 earnings per share (EPS) estimates for Theravance Biopharma in a ...Dakota Financial News, 3 months ago